HSBC ON SUN PHARMA
ACCUMULATE
TP ₹2,120
• MFN deal removes tariff overhang for Sun Pharma for the next two years.
• Sees limited impact of ~2% on FY29 EPS estimates; awaits further clarity.
• Tariff concerns ease following the deal.
1September 3, 2026 919 1